Novartis AG
PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE

Last updated:

Abstract:

PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

Status:
Application
Type:

Utility

Filling date:

12 Mar 2021

Issue date:

16 Dec 2021